SARS-CoV-2-IN-7 demonstrates potent inhibition of viral replication in SARS-CoV-2-infected Vero E6 cells with an IC50 value of 844 nM.

SARS-CoV-2 Mpro-IN-7 (compound 6g) effectively inhibits SARS-CoV-2 main protease (Mpro) with an IC50 value of 8.8 μM and exhibits a cytotoxic concentration (CC50) of 10 μM [1].

SARS-CoV-2 3CLpro-IN-7 is a reversible covalent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an inhibitory concentration (IC50) value of 1.4 µM.

Hydroxychloroquine (2-[[4-[(7-Chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol) (HCQ) is an alkalinizing lysosomatropic drug that acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR7/9. It is a medication used to prevent and treat malaria, and it's also being studied as an experimental treatment for COVID-19.

Hydroxychloroquine sulfate (Acidum iopanoicum) inhibits plasmodial heme polymerase. It is a chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa.

Hydroxychloroquine-d5 is a deuterated compound of Hydroxychloroquine. Hydroxychloroquine has a CAS number of 118-42-3. Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR7/9. It is a medication used to prevent and treat malaria, and it's also being studied as an experimental treatment for COVID-19.

RdRP-IN-7, a RNA-dependent RNA polymerase (RdRp) inhibitor, demonstrates efficacy against SARS-CoV-2 infection with an inhibitory concentration (IC50) of 8.2 μM and (IC90) of 14.1 μM, alongside a cytotoxic concentration (CC90) of 79.1 μM, rendering it suitable for antiviral research [1].

Hydroxychloroquine Impurity E, an impurity found in Hydroxychloroquine, a synthetic antimalarial compound that also inhibits Toll-like receptor 7/9 (TLR7/9) signaling, has been shown to effectively inhibit SARS-CoV-2 infection in vitro [1] [2] [3].

Chloroquine-d5 is a deuterated compound of Chloroquine. Chloroquine has a CAS number of 54-05-7. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro with EC50 of 1.13 μM.

SARS-CoV-2 nsp14-IN-3 (4975) is a potent inhibitor targeting the N7-Methyltransferase activity of SARS-CoV-2 nonstructural protein 14 (Nsp14), with an IC50 value of 3.5 μM [1].

MMT5-14 is a SARS-CoV-2 inhibitor. MMT5-14 showed 2- to 7-fold higher antiviral activity in four variants of SARS-CoV-2. By reducing premature hydrolysis in hamsters, MMT5-14 increased the prodrug concentration by 200- to 300-fold in the plasma and lungs but also enhanced lung accumulation of the active metabolite triphosphate nucleosides (NTP) by 5-fold.

Mpro inhibitor N3 hemihydrate is a potent antagonist of the SARS-CoV-2 main protease (Mpro), demonstrating an EC50 of 16.77 μM against SARS-CoV-2. It exhibits specific inhibition of Mpro in a range of coronaviruses, including SARS-CoV and MERS-CoV. Furthermore, it effectively inhibits HCoV-229E, FIPV, and MHV-A59, with IC50 values of 4.0 μM, 8.8 μM, and 2.7 μM, respectively[1][2].

Hydroxychloroquine Impurity F, an impurity in Hydroxychloroquine, is identified in the synthetic antimalarial agent known for its capability to inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Additionally, Hydroxychloroquine demonstrates effective inhibition of SARS-CoV-2 infection in vitro [1] [2] [3].